Keunchil Park1, Eric B Haura2, Natasha B Leighl3, Paul Mitchell4, Catherine A Shu5, Nicolas Girard6, Santiago Viteri7, Ji-Youn Han8, Sang-We Kim9, Chee Khoon Lee10, Joshua K Sabari11, Alexander I Spira12, Tsung-Ying Yang13, Dong-Wan Kim14, Ki Hyeong Lee15, Rachel E Sanborn16, José Trigo17, Koichi Goto18, Jong-Seok Lee19, James Chih-Hsin Yang20, Ramaswamy Govindan21, Joshua M Bauml22, Pilar Garrido23, Matthew G Krebs24, Karen L Reckamp25, John Xie26, Joshua C Curtin26, Nahor Haddish-Berhane26, Amy Roshak26, Dawn Millington26, Patricia Lorenzini26, Meena Thayu26, Roland E Knoblauch26, Byoung Chul Cho27. 1. Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. 2. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. 3. Princess Margaret Cancer Centre, Toronto, Canada. 4. Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Heidelberg, Australia. 5. Columbia University Medical Center, New York, NY. 6. Institut Curie, Paris, France. 7. Instituto Oncológico Dr Rosell, Hospital Universitari Dexeus, Grupo QuironSalud, Barcelona, Spain. 8. National Cancer Center, Gyeonggi-do, South Korea. 9. Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 10. St George Hospital, Kogarah, Australia. 11. New York University School of Medicine, New York, NY. 12. Virginia Cancer Specialists Research Institute, US Oncology Research, Fairfax, VA. 13. Taichung Veterans General Hospital, Taiwan, China. 14. Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea. 15. Chungbuk National University Hospital, Cheongju, South Korea. 16. Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR. 17. Hospital Universitario Virgen de la Victoria y Regional, IBIMA, Malaga, Spain. 18. National Cancer Center Hospital East, Kashiwa, Japan. 19. Seoul National University Bundang Hospital, Seongnam, South Korea. 20. National Taiwan University Cancer Center, Taiwan, China. 21. Washington University School of Medicine, St Louis, MO. 22. Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. 23. Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain. 24. Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom. 25. City of Hope Comprehensive Cancer Center, Duarte, CA. 26. Janssen R&D, Spring House, PA. 27. Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Abstract
PURPOSE: Non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody with immune cell-directing activity, binds to each receptor's extracellular domain, bypassing resistance at the tyrosine kinase inhibitor binding site. METHODS: CHRYSALIS is a phase I, open-label, dose-escalation, and dose-expansion study, which included a population with EGFR Exon20ins NSCLC. The primary end points were dose-limiting toxicity and overall response rate. We report findings from the postplatinum EGFR Exon20ins NSCLC population treated at the recommended phase II dose of 1,050 mg amivantamab (1,400 mg, ≥ 80 kg) given once weekly for the first 4 weeks and then once every 2 weeks starting at week 5. RESULTS: In the efficacy population (n = 81), the median age was 62 years (range, 42-84 years); 40 patients (49%) were Asian, and the median number of previous lines of therapy was two (range, 1-7). The overall response rate was 40% (95% CI, 29 to 51), including three complete responses, with a median duration of response of 11.1 months (95% CI, 6.9 to not reached). The median progression-free survival was 8.3 months (95% CI, 6.5 to 10.9). In the safety population (n = 114), the most common adverse events were rash in 98 patients (86%), infusion-related reactions in 75 (66%), and paronychia in 51 (45%). The most common grade 3-4 adverse events were hypokalemia in six patients (5%) and rash, pulmonary embolism, diarrhea, and neutropenia in four (4%) each. Treatment-related dose reductions and discontinuations were reported in 13% and 4% of patients, respectively. CONCLUSION: Amivantamab, via its novel mechanism of action, yielded robust and durable responses with tolerable safety in patients with EGFR Exon20ins mutations after progression on platinum-based chemotherapy.
PURPOSE: Non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody with immune cell-directing activity, binds to each receptor's extracellular domain, bypassing resistance at the tyrosine kinase inhibitor binding site. METHODS: CHRYSALIS is a phase I, open-label, dose-escalation, and dose-expansion study, which included a population with EGFR Exon20ins NSCLC. The primary end points were dose-limiting toxicity and overall response rate. We report findings from the postplatinum EGFR Exon20ins NSCLC population treated at the recommended phase II dose of 1,050 mg amivantamab (1,400 mg, ≥ 80 kg) given once weekly for the first 4 weeks and then once every 2 weeks starting at week 5. RESULTS: In the efficacy population (n = 81), the median age was 62 years (range, 42-84 years); 40 patients (49%) were Asian, and the median number of previous lines of therapy was two (range, 1-7). The overall response rate was 40% (95% CI, 29 to 51), including three complete responses, with a median duration of response of 11.1 months (95% CI, 6.9 to not reached). The median progression-free survival was 8.3 months (95% CI, 6.5 to 10.9). In the safety population (n = 114), the most common adverse events were rash in 98 patients (86%), infusion-related reactions in 75 (66%), and paronychia in 51 (45%). The most common grade 3-4 adverse events were hypokalemia in six patients (5%) and rash, pulmonary embolism, diarrhea, and neutropenia in four (4%) each. Treatment-related dose reductions and discontinuations were reported in 13% and 4% of patients, respectively. CONCLUSION: Amivantamab, via its novel mechanism of action, yielded robust and durable responses with tolerable safety in patients with EGFR Exon20ins mutations after progression on platinum-based chemotherapy.
Authors: Hiroyuki Yasuda; Eunyoung Park; Cai-Hong Yun; Natasha J Sng; Antonio R Lucena-Araujo; Wee-Lee Yeo; Mark S Huberman; David W Cohen; Sohei Nakayama; Kota Ishioka; Norihiro Yamaguchi; Megan Hanna; Geoffrey R Oxnard; Christopher S Lathan; Teresa Moran; Lecia V Sequist; Jamie E Chaft; Gregory J Riely; Maria E Arcila; Ross A Soo; Matthew Meyerson; Michael J Eck; Susumu S Kobayashi; Daniel B Costa Journal: Sci Transl Med Date: 2013-12-18 Impact factor: 17.956
Authors: M E Arcila; H A Yu; J Naidoo; C S Sima; K Rodriguez; N Busby; K Nafa; M Ladanyi; G J Riely; M G Kris Journal: Cancer Date: 2015-06-10 Impact factor: 6.860
Authors: M Beau-Faller; N Prim; A-M Ruppert; I Nanni-Metéllus; R Lacave; L Lacroix; F Escande; S Lizard; J-L Pretet; I Rouquette; P de Crémoux; J Solassol; F de Fraipont; I Bièche; A Cayre; E Favre-Guillevin; P Tomasini; M Wislez; B Besse; M Legrain; A-C Voegeli; L Baudrin; F Morin; G Zalcman; E Quoix; H Blons; J Cadranel Journal: Ann Oncol Date: 2013-11-26 Impact factor: 32.976
Authors: Smruthi Vijayaraghavan; Lorraine Lipfert; Kristen Chevalier; Barbara S Bushey; Benjamin Henley; Ryan Lenhart; Jocelyn Sendecki; Marilda Beqiri; Hillary J Millar; Kathryn Packman; Matthew V Lorenzi; Sylvie Laquerre; Sheri L Moores Journal: Mol Cancer Ther Date: 2020-08-03 Impact factor: 6.261
Authors: Maria E Arcila; Khedoudja Nafa; Jamie E Chaft; Natasha Rekhtman; Christopher Lau; Boris A Reva; Maureen F Zakowski; Mark G Kris; Marc Ladanyi Journal: Mol Cancer Ther Date: 2013-01-31 Impact factor: 6.261
Authors: Jiyeon Yun; Soo-Hwan Lee; Seok-Young Kim; Seo-Yoon Jeong; Jae-Hwan Kim; Kyoung-Ho Pyo; Chae-Won Park; Seong Gu Heo; Mi Ran Yun; Sangbin Lim; Sun Min Lim; Min Hee Hong; Hye Ryun Kim; Meena Thayu; Joshua C Curtin; Roland E Knoblauch; Matthew V Lorenzi; Amy Roshak; Byoung Chul Cho Journal: Cancer Discov Date: 2020-05-15 Impact factor: 39.397
Authors: Stephen W Jarantow; Barbara S Bushey; Jose R Pardinas; Ken Boakye; Eilyn R Lacy; Renouard Sanders; Manuel A Sepulveda; Sheri L Moores; Mark L Chiu Journal: J Biol Chem Date: 2015-08-10 Impact factor: 5.157
Authors: Shuyu Huang; Sander M J van Duijnhoven; Alice J A M Sijts; Andrea van Elsas Journal: J Cancer Res Clin Oncol Date: 2020-09-28 Impact factor: 4.553
Authors: Na Wang; Yili Zhu; Ying Wu; Bo Huang; Junhua Wu; Ruiguang Zhang; Jun Fan; Xiu Nie Journal: J Cancer Res Clin Oncol Date: 2022-07-29 Impact factor: 4.322
Authors: James Chih-Hsin Yang; Martin Schuler; Sanjay Popat; Satoru Miura; Keunchil Park; Antonio Passaro; Filippo De Marinis; Flavio Solca; Angela Märten; Edward S Kim Journal: Front Oncol Date: 2022-04-28 Impact factor: 5.738